Stock Analysis

Coca-Cola Europacific Partners plc Ordinary SharesCCEP

Price:$112.40Market Closed+2.40%at last close

Sector: Consumer Defensive

AnalystsBuy23 analysts

Mkt Cap 49.39BDiv Yield 2.13%ROE 24.8%

Low $85.43$112.40High $112.40

Price is 100% of the way from the year's low to its high.

PMP Verdict

Insufficient financial data

No financial statements on file for this ticker — fundamental scores are not computed.

Market context

+2.4% today· Z 1.5σ

Bull Case

✓ROE 24.8% — efficient capital deployment
✓Interest coverage 13.9× — debt well covered

What's happening with CCEP

Coca-Cola Europacific Partners (ENXTAM:CCEP) Could Be 30% Undervalued After Capacity Expansion — Yahoo, 1d agoLast big move: +2.9% on 2026-10-08

About Coca-Cola Europacific Partners plc Ordinary Shares

CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. Show more

In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.

Employees: 41,000 · Website ↗

Price History

Weekly Candlestick Chart — up to 5Y

Key Metrics

Financial snapshot · Tap any metric for its definition and grade

Valuation

55C

P/E (TTM)—

Price / TTM EPS (own statements)

P/FCF21.2xB

Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative

FCF Yield4.7%C

Grade C: LowInverse of Finnhub P/FCF (own TTM FCF unavailable)

P/S (TTM)1.43xA

Grade A: CheapPrice / TTM Revenue (own statements)

EV/EBITDA14.7xB

Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral

EV/Sales—

Enterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple

Forward P/E18.7xB

Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth

P/B Ratio5.09xC

Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks

PEG Ratio2.03C

Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)

Dividend Yield2.13%A

Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress

Payout Ratio46.3%A

Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable

Profitability

25E

ROIC—

NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat

ROE24.8%A

Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks

ROA6.4%C

Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit

Net Margin9.4%C

Grade C: AverageNet Income / Revenue

Operating Margin—

TTM EBIT / TTM Revenue

Gross Margin36.3%C

Grade C: AverageGross Profit / Revenue

FCF Margin—

FCF / Revenue

True FCF Margin—

TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost

Growth

Revenue CAGR—

Compound annual revenue growth (up to 5Y depending on data availability)

Net Income CAGR—

Compound annual net income growth (up to 5Y depending on data availability)

EPS CAGR (5Y)—

Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0

Implied EPS Growth—

Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth

Dilution (5Y)—

Share count change over 5Y

SBC / Net Income—

Stock-based comp/Net income. >30% = dilution risk

SBC / Revenue—

TTM stock-based comp / TTM Revenue

Financial Health

31D

Altman Z-Score—

Bankruptcy risk. >3 Safe, <1.8 Distress

Current Ratio0.89xD

Grade D: LowCurrent Assets/Liabilities

Quick Ratio0.68xC

Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory

Interest Coverage13.9xA

Grade A: StrongEBIT/Interest. >10 Strong

Debt Repayment—

Years to repay net debt via FCF

Net Debt/EBIT—

Leverage. <2x Low, >4x High

Debt/Equity1.47xC

Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.

Cash / Debt—

Cash covers how much of total debt. >1 = could repay all debt from cash

Quality

Piotroski F-Score—

Financial strength 0–9. >7 Strong

Beneish M-Score—

Earnings manipulation risk. < -2.22 Safe

FCF Conversion—

FCF / Net Income

Margin Stability—

EBIT margin std deviation. Lower = stable

Capex / Revenue—

TTM CapEx / TTM Revenue — high % = capital-hungry business

Asset Turnover0.60xC

Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales

Insider Transactions

SEC Form 4 · 8 records

Open-market · 90dBuy —Sell —Other filings 15No open-market trades

P/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.

Recent insider transactions
Trade date	Insider	Transaction	Shares	Filed
2026-09-21 Stephen Moorhouse Filed 2026-09-22	Stephen Moorhouse	Buy	+2	2026-09-22
2026-09-21 Leendert den Hollander Filed 2026-09-22	Leendert den Hollander	Buy	+2	2026-09-22
2026-09-21 Stephen Lusk Filed 2026-09-22	Stephen Lusk	Buy	+2	2026-09-22
2026-09-21 Stephen Lusk Filed 2026-09-22	Stephen Lusk	Buy	+2	2026-09-22
2026-09-21 Svetlana Walker Filed 2026-09-22	Svetlana Walker	Buy	+2	2026-09-22

Show 3 more filings

Additional recent insider transactions
Trade date	Insider	Transaction	Shares	Filed
2026-09-21 Edward Walker Filed 2026-09-22	Edward Walker	Buy	+8	2026-09-22
2026-09-21 Edward Walker Filed 2026-09-22	Edward Walker	Buy	+2	2026-09-22
2026-08-19 Stephen Moorhouse Filed 2026-08-20	Stephen Moorhouse	Buy	+2	2026-08-20

More metrics — Moat, Per Share, Balance Sheet, Market

Moat

ROIC >12% Years—

Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability

Gross Margin (Med.)—

Median annual gross margin across available fiscal years — pricing-power durability

FCF-Positive Years—

Share of completed fiscal years with positive free cash flow

Net Margin Floor—

Weakest annual net margin across completed fiscal years — recession/downcycle resilience

Per Share

EPS (TTM)—

TTM net income per share (Finnhub fallback)

Cash / Share$4.50

Cash & short-term investments per share (Finnhub)

Book Value / Share$18.68

Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks

Balance Sheet

Total Debt—

Total debt obligations (short + long term)

Cash & Equiv.—

Cash and short-term investments

Net Debt—

Total Debt minus Cash. Negative = Net Cash position

Total Equity—

Shareholders' equity (book value)

Asset / Liability—

Total Assets / Total Liabilities

Market

Market Cap$49.39B

Current Market Capitalization

Beta0.52B

Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings

How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.

Ratio snapshot Oct 17, 2026

Key Insights: Coca-Cola Europacific Partners plc Ordinary Shares (CCEP)

CCEP is up 2.40% at the last close. Return on equity of 24.8% is well above the market average.

The stock currently yields 2.1% in dividends.

See how CCEP ranks on the Capex Tracker — top 50 capital spenders compared.

Recent Market Moves

See all CCEP moves →

Date	Session	Price	Move	Z-Score
Oct 8	Regular	103.78	+2.90%	2.45
Oct 8	After-hours	103.73	+2.85%	2.41

Frequently Asked Questions about CCEP

What is the current Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) stock price?

CCEP is trading at $112.40 at the last market close, up 2.40% on the session. PreMarketPrice tracks CCEP pre-market, intraday and after-hours prices.

Is CCEP stock a buy right now?

PreMarketPrice's quantitative model rates Coca-Cola Europacific Partners plc Ordinary Shares's financial health at 31/100. This is a data-driven snapshot of fundamentals, not investment advice.

Is CCEP stock overvalued?

Coca-Cola Europacific Partners plc Ordinary Shares trades at a trailing P/E of n/a and our valuation score rates it 55/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.

When does Coca-Cola Europacific Partners plc Ordinary Shares report earnings?

No confirmed earnings date is currently scheduled for CCEP. The Earnings section lists recent reports and updates as dates are announced.

What sector does Coca-Cola Europacific Partners plc Ordinary Shares operate in?

Coca-Cola Europacific Partners plc Ordinary Shares operates in the Consumer Defensive sector. The Related Stocks section lists sector peers for comparison.

What does Coca-Cola Europacific Partners plc Ordinary Shares do?

CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia.

About Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) Stock

Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) is a US-listed stock operating in the Consumer Defensive sector. As of the latest update, Coca-Cola Europacific Partners plc Ordinary Shares is trading at $112.40, up 2.40% on the day with a market capitalization of $49.4 billion. The financial health score for CCEP is 31/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for CCEP stock.

CCEP Stock Analysis & Key Metrics

On PreMarketPrice, you can track Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) across multiple dimensions:

Pre-market price & movement: Real-time CCEP stock price with percentage change, updated continuously during pre-market and regular trading hours.
Valuation & P/E history: Historical P/E, P/S, and P/B ratios for CCEP with trend analysis and normalized valuation multiples.
Financial statements: Revenue, net income, assets, liabilities, and equity for Coca-Cola Europacific Partners plc Ordinary Shares across multiple reporting periods.
Financial health score: A composite score of 31/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for CCEP.
Sector peers: Compare CCEP against 2 other consumer defensive stocks on key financial metrics.

Is CCEP a Good Stock to Buy?

This page provides data-driven analysis to help you evaluate Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) as an investment. The financial health score of 31/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.

Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.

Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) Premarket Movers →Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) Valuation & P/E History →Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) Financial Statements →Coca-Cola Europacific Partners plc Ordinary Shares (CCEP) Unusual Moves & Catalyst History — GainersLosers →CCEP Stock CVThe whole company on one page — stockcv.com Writing about CCEP? Embed this CV card on your site →

Related opportunities

Moving today in Consumer Defensive

BTI+3.1%Z 2.2σ UL+2.5%Z 2.0σ

All movers today →Consumer Defensive sector overview →